27693948|t|Molecular simulation study on concentration effects of rofecoxib with POPC bilayer
27693948|a|The interactions between rofecoxib and POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) bilayer were studied using all-atom molecular dynamics simulation method. Four POPC bilayer systems with different number of rofecoxib molecules were constructed to simulate different drug concentration. The free energy of rofecoxib passing across pure POPC bilayer has two minima (at z âˆ¼1.2nm or 1.6nm). As for the high concentration model, the minimum of the free energy profile slightly shifts to the bilayer center. Moreover, the energy change from bulk water to POPC bilayer increases while the central barrier to cross the hydrophobic core of bilayer slightly decreases, suggesting that increasing drug concentration makes it favorable for rofecoxib to partition into the bilayer and easier to pass across bialyer center. Energy analysis show that the stabilization between the selected rofecoxib and other pre-inserted rofecoxib molecule is mainly due to van der Waals interaction energy. The predicted permeability of rofecoxib in high concentration model slightly weakens as compared with low concentration model.
27693948	21	26	study	T062	UMLS:C2603343
27693948	55	64	rofecoxib	T103	UMLS:C0762662
27693948	70	74	POPC	T103	UMLS:C0044576
27693948	75	82	bilayer	T017	UMLS:C0023768
27693948	87	99	interactions	T038	UMLS:C0687133
27693948	108	117	rofecoxib	T103	UMLS:C0762662
27693948	122	126	POPC	T103	UMLS:C0044576
27693948	127	177	(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)	T103	UMLS:C0044576
27693948	178	185	bilayer	T017	UMLS:C0023768
27693948	191	198	studied	T062	UMLS:C2603343
27693948	244	250	method	T170	UMLS:C0025663
27693948	257	261	POPC	T103	UMLS:C0044576
27693948	262	269	bilayer	T017	UMLS:C0023768
27693948	303	312	rofecoxib	T103	UMLS:C0762662
27693948	362	366	drug	T103	UMLS:C1254351
27693948	401	410	rofecoxib	T103	UMLS:C0762662
27693948	431	435	POPC	T103	UMLS:C0044576
27693948	436	443	bilayer	T017	UMLS:C0023768
27693948	513	518	model	T170	UMLS:C0026344
27693948	582	589	bilayer	T017	UMLS:C0023768
27693948	590	596	center	T082	UMLS:C0205099
27693948	645	649	POPC	T103	UMLS:C0044576
27693948	650	657	bilayer	T017	UMLS:C0023768
27693948	678	685	central	T082	UMLS:C0205099
27693948	686	693	barrier	T038	UMLS:C0028778
27693948	727	734	bilayer	T017	UMLS:C0023768
27693948	782	786	drug	T103	UMLS:C1254351
27693948	810	819	favorable	T033	UMLS:C0278250
27693948	824	833	rofecoxib	T103	UMLS:C0762662
27693948	856	863	bilayer	T017	UMLS:C0023768
27693948	890	897	bialyer	T017	UMLS:C0023768
27693948	898	904	center	T082	UMLS:C0205099
27693948	913	921	analysis	T062	UMLS:C0936012
27693948	971	980	rofecoxib	T103	UMLS:C0762662
27693948	1004	1013	rofecoxib	T103	UMLS:C0762662
27693948	1104	1113	rofecoxib	T103	UMLS:C0762662
27693948	1136	1141	model	T170	UMLS:C0026344
27693948	1194	1199	model	T170	UMLS:C0026344